Study of BEBT-109 for lung cancer with EGFR exon 20 insertion mutation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer that is advanced (stage IIIB/IIIC) or has spread (stage IV) and cannot be removed by surgery.
- Your cancer has a specific change in the EGFR gene called an exon 20 insertion mutation, confirmed by a blood or tissue test.
- You have not had any prior treatment for this stage of lung cancer, but previous treatments like chemotherapy or targeted therapy before the cancer spread are okay if they ended more than 6 months ago.
- You are at least 18 years old and able to care for yourself (ECOG score 0-1).
- You have at least one tumor that can be measured on scans and have adequate organ function (kidney, liver, and blood counts) as determined by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.